Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Potent and Safe Anti-Itch Product

Non-steroidal OTC or potential Rx anti-itch product

Mechanism of action

inhibition of C-nociceptors by strontium compound

Full description

TriCalm is a turn-key potent OTC anti-itch system providing potent and immediate itch relief by utilizing a strontium based compound.  Well-controlled human clinical trials conducted by Cosmederm and by non-Cosmederm investigators demonstrate the strontium can selectively suppress the symptoms of sensory irritation (stinging, burning and itching) without affecting other cutaneous sensations.  These studies demonstrate that topically applied strontium can substantially suppress itch caused by a variety of chemical irritants, including histamine, as well as itch triggered by an IgE-medicated allergic response (Type I hypersensitivity) which contributes to the pathogenesis and itching of atopic dermatitis and other itch-associated conditions.

Additionally, reports from physicians as well as clinical observations at Cosmederm suggest that strontium can also rapidly surrpress itch caused by delayed-type allergies (DTH - Type IV hypersensitivity) that cause poison ivy/oak/sumac, "jewelry (nickel) allergy"; neuropathy-associated itching caused by healing wounds and would dressing adhesives and other irritating skin conditions.  However, well controlled clinical trials are required to confirm these clinical reports.

TriCalm is equally effective for treating itching on animals.

Cosmederm is currently conducting proof of principle studies to determine the viability a more potent version of TriCalm as an Rx product.  go to www.cosmederm.com/download for published articles

Development status

Registered

Patent information

 Patented in all major world markets.

Type of business relationship sought

Cosmederm is amenable to a variety of different relationships including acquisition, licensing, joint venture/co-development or distribution.

Licensing contact

Sean Edwards
President/CEO
Request more information

More information

For more information about the product please visit website.

Company details

Cosmederm Technologies
Cosmederm Technologies develops novel technologies for the dermatology field

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Partnering consultation free of charge
EthyPharm
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us